April 30, 2026

GRAND RAPIDS, Mich., April 30, 2026 /PRNewswire/ — Capitan Orthopedics, Inc. (https://capitanortho.com/) announced today that it has been granted Breakthrough Device Designation from the U.S. Food & Drug Administration (FDA) for its SupraSpacerTM implant.

FDA authorization marks critical milestone enabling advancement of next-generation bone regeneration therapy for patients with degenerative spinal diseases